{
    "ticker": "SNDX",
    "name": "Syndax Pharmaceuticals, Inc.",
    "description": "Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on innovative cancer therapies that address significant unmet medical needs. Founded in 2005 and headquartered in San Diego, California, Syndax is dedicated to developing a portfolio of targeted therapies that aim to improve treatment outcomes for cancer patients. The company's lead product candidate, axatilimab, is a monoclonal antibody designed to inhibit the activity of the immune checkpoint receptor known as PD-1, and is currently undergoing clinical trials in various malignancies, including hematological cancers. Syndax is also advancing other oncology-focused candidates, including entinostat, a selective histone deacetylase (HDAC) inhibitor, which has shown promise in combination with immune checkpoint inhibitors. With a strong emphasis on scientific innovation and a robust pipeline, Syndax is committed to transforming the treatment landscape for cancer, aiming to extend the lives of patients while enhancing their quality of life. The company collaborates with leading academic institutions and research organizations to accelerate the development of its therapies and aims to bring new hope to patients battling cancer.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "San Diego, California, USA",
    "founded": "2005",
    "website": "https://www.syndax.com",
    "ceo": "Brent S. Nesmith",
    "social_media": {
        "twitter": "https://twitter.com/SyndaxPharma",
        "linkedin": "https://www.linkedin.com/company/syndax-pharmaceuticals"
    },
    "investor_relations": "https://ir.syndax.com",
    "key_executives": [
        {
            "name": "Brent S. Nesmith",
            "position": "CEO"
        },
        {
            "name": "Michael W. B. Kauffman",
            "position": "CBO"
        }
    ],
    "product_categories": [
        {
            "category": "Oncology Therapies",
            "products": [
                "Axatilimab",
                "Entinostat"
            ]
        }
    ],
    "seo": {
        "meta_title": "Syndax Pharmaceuticals, Inc. | Innovative Cancer Therapies",
        "meta_description": "Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for cancer treatment, focusing on unmet medical needs.",
        "keywords": [
            "Syndax Pharmaceuticals",
            "Cancer Treatments",
            "Biotechnology",
            "Pharmaceuticals",
            "Oncology",
            "Axatilimab",
            "Entinostat"
        ]
    },
    "faq": [
        {
            "question": "What does Syndax Pharmaceuticals focus on?",
            "answer": "Syndax Pharmaceuticals focuses on developing innovative cancer therapies that address significant unmet medical needs."
        },
        {
            "question": "Who is the CEO of Syndax Pharmaceuticals?",
            "answer": "Brent S. Nesmith is the CEO of Syndax Pharmaceuticals, Inc."
        },
        {
            "question": "Where is Syndax Pharmaceuticals headquartered?",
            "answer": "Syndax Pharmaceuticals is headquartered in San Diego, California, USA."
        },
        {
            "question": "What are the main product candidates of Syndax?",
            "answer": "The main product candidates include axatilimab and entinostat, both targeting cancer treatment."
        },
        {
            "question": "When was Syndax Pharmaceuticals founded?",
            "answer": "Syndax Pharmaceuticals was founded in 2005."
        }
    ],
    "competitors": [
        "NKTR",
        "INCY",
        "CLDX",
        "ASRT"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "BMY",
        "REGN"
    ]
}